Asia-Pacific dominates the apixaban market due to increasing healthcare initiatives by respective governments, an increase in elderly population, an increase in obesity prevalence, a rise in healthcare expenditures worldwide, and a growth in government and private organisations in this area. Europe is expected to be the fastest growing region in terms of apixaban market growth due to rising prevalence of venous thromboembolism-related conditions, rising therapeutic indications for apixaban, rising surge in global healthcare expenditures, and increasing government and private organisations investing significantly in healthcare research and development in this region.
Read More:
https://knackersblogger.blogspot.com/2022/10/apixaban-market-size-share-outlook-and.html
